Biomarkers of Uterine Muscle Physiology

Recruiting

• Conditions: Labor (Obstetrics)--Complications; Labor; Dyscoordinate

• Registration Number: NCT04251702
• Lead Sponsor: University of Colorado, Denver

Brief Summary

This observational study characterizes the relationship between amniotic fluid lactate and uterine electromyography during labor in healthy individuals at term planning a vaginal birth. Additional comparison measures and outcomes measures will be collected and analyzed as exploratory measures.

Detailed Description

Elevated amniotic fluid lactate (AFL) and uterine electromyography (EMG) mathematically transformed to calculated the power density spectrum median frequency have been found separately to be associated with labor dystocia and cesarean birth. Similarly, recent research indicates that the cytokine IL-6 may play a critical role in labor onset and potentially labor progression. All three are hypothesized to reflect that uterine fatigue plays a role in the pathophysiology of labor dystocia for some women.

This study aims to characterize the relationship between these three measures to better understand the role of uterine fatigue in labor dystocia and triangulate biomarkers of fatigue that may lead to a better understanding of labor dystocia phenotypes.

In addition to the primary measures, comparison measures will be collected. For AFL comparison, venous whole blood lactate and capillary lactate will be collected and measured using both a point-of-care lactate meter (Stat Strip Lactate Meter, Nova Biomedical) and a table-top blood gas analyzer (Nova Prime). For EMG comparison, routine contraction monitoring data will be collected and compared to the EMG signal. IL-6 will be measured both in blood and amniotic fluid using a novel microsampling protocol. Three visual analog scales on women's experiences of fatigue, anxiety, and pain will also be administered.

Additional data will be collected from the medical record to perform exploratory and hypothesis generating analysis.

Study Timeline

• Study First Submitted: 2020-01-30
• Study First Submitted QC: 2020-01-30
• Study First Posted: 2020-02-05
• Study Start: 2023-08-21
• Status Verified: 2023-11
• Last Update Submitted: 2023-11-17
• Last Update Posted: 2023-11-21
• Primary Completion: 2024-03
• Study Completion: 2024-07

Recruitment & Eligibility

• Status: RECRUITING
• Sex: Female
• Target Recruitment: 46

Inclusion Criteria

• Maternal age: 18-41 years at the due date
• Term gestation: 37-41 weeks estimated gestational age (EGA)
• Single fetus in a vertex presentation: Pregnancy with only one fetus that is in a head down position with the occiput leading into the pelvis upon admission to the hospital.

Read More

Exclusion Criteria

• Pre-existing or gestational diabetes requiring medical management: The diagnosis of diabetes of any kind requiring management with medications including but not limited to insulin, glyburide, and metformin as indicated in the health record.
• Pre-existing or gestational hypertension or pre-eclampsia requiring medical management: The diagnosis of hypertension of any kind requiring management with medications including but not limited to long-term hypertension management such as methyldopa and short-term or emergency hypertension management such as labetalol or magnesium sulfate as indicated in the health record.
• Suspected fetal anomaly or intrauterine growth restriction: Any diagnosed fetal anomalies or intrauterine growth restriction as indicated in the health record.
• Use of amnioinfusion prior to sample collection: Amnioinfusion, the infusion of fluids into the uterus using an intrauterine catheter may affect AFL concentrations. Any amnioinfusion prior to sample collection will exclude participants from continued participation.
• Fetal distress prior to or during sample collection: Category 3 fetal heart tracing as defined by the National Institute of Child Health and Development22, absent fetal heart rate variability with recurrent late deceleration, recurrent variable decelerations, bradycardia, or sinusoidal rhythm.

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Median power density spectrum of uterine electromyography	30 minutes after amniotic fluid collection during active labor (4-10cm) after rupture of membranes	Uterine electromyography measured using the Bloomlife Lovelace EMG monitor
Amniotic Fluid Lactate	During active labor (4-10cm) after rupture of membranes	Amniotic fluid lactate as measured using the handheld StatStrip Lactate Meter (Nova Biomedical). This will be measured once during active labor (6-10cm) after rupture of membranes.
Visual analog scale for fatigue	At the time of amniotic fluid collection	Participants indicate their level of fatigue on a 100 mm horizontal line anchored by "no fatigue at all" (0) and "the most serious fatigue imaginable" (100). The scale will be administered at the time of amniotic fluid collection.
Amniotic fluid IL-6	At the time of amniotic fluid collection	Amniotic fluid collected using a volumetric assisted microsampling device.

Secondary Outcome Measures

Name	Time	Method
Serum Lactate	At the time of amniotic fluid collection	Serum lactate measured using a POC device and analyzed using a laboratory assay
Capillary Lactate	At the time of amniotic fluid collection	Capillary lactate measured using the handheld StatStrip Lactate Meter (Nova Biomedical). This will be measured within 10 minutes of the amniotic fluid lactate measurement.
Serum IL-6	At the time of amniotic fluid collection	Serum IL-6 measured using a laboratory assay (multiplex)

Trial Locations

Locations (1)

UCHealth Hospital; 🇺🇸 Aurora, Colorado, United States